Bicara Therapeutics’ (BCAX) “Market Outperform” Rating Reiterated at Citizens Jmp

Citizens Jmp reissued their market outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report released on Tuesday,Benzinga reports. Citizens Jmp currently has a $31.00 target price on the stock.

A number of other research analysts have also commented on BCAX. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Finally, Citigroup began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Trading Up 4.7%

Shares of NASDAQ:BCAX opened at $21.47 on Tuesday. The firm’s 50 day moving average is $17.36 and its two-hundred day moving average is $16.73. The firm has a market capitalization of $1.41 billion, a P/E ratio of -8.49 and a beta of -1.23. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $21.50.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. Analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Insiders Place Their Bets

In other news, insider David Raben sold 16,300 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the completion of the sale, the insider owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This trade represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $19.66, for a total value of $245,750.00. Following the transaction, the chief operating officer owned 200,641 shares in the company, valued at $3,944,602.06. This represents a 5.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 137,969 shares of company stock worth $2,586,198 over the last three months. Company insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors have recently bought and sold shares of the business. Bleakley Financial Group LLC acquired a new position in Bicara Therapeutics in the 3rd quarter valued at approximately $481,000. Cantor Fitzgerald L. P. purchased a new stake in Bicara Therapeutics in the 3rd quarter worth approximately $1,579,000. Schroder Investment Management Group boosted its stake in shares of Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after buying an additional 383,681 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Bicara Therapeutics by 160.9% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock valued at $922,000 after buying an additional 61,201 shares during the period. Finally, SCS Capital Management LLC purchased a new position in shares of Bicara Therapeutics during the 2nd quarter valued at $496,000.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.